Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021

Rhea-AI Summary

Entasis Therapeutics Holdings announced it will disclose its third quarter 2021 financial results on November 4, 2021, before market opening. A conference call and webcast will take place at 8:00 AM ET to discuss the results and provide updates on clinical and corporate matters, followed by a Q&A session. Investors can access the call by phone or through a provided link. Entasis focuses on developing innovative antibacterial products targeting serious infections from multidrug-resistant Gram-negative bacteria, with a pipeline that includes several advanced candidates.

WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report third quarter 2021 financial results before the market opens on November 4, 2021. The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. A question-and-answer session will follow management’s prepared remarks.

Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes prior to the start of the call by dialing 888-394-8218 (U.S.) or 323-701-0225 (international) or through the link Entasis Therapeutics Third Quarter 2021 Earnings Conference Call. A replay of the call will be available from the Entasis website at www.entasistx.com following the call.

About Entasis
Entasis is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including post Phase 3 sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0462 (targeting multiple Gram-negative pathogens including Pseudomonas aeruginosa) and ETX0282CPDP (targeting Enterobacteriaceae infections). For more information, visit www.entasistx.com.

Entasis Contacts
Company Contact	Investor Contact
Kyle Dow	Bruce Mackle
Entasis Therapeutics	LifeSci Advisors
(781) 810-0114	(929) 469-3859
kyle.dow@entasistx.com	bmackle@lifesciadvisors.com
Media Contact
Brett Whelan
LifeSci Communications
(215) 315 3143
bwhelan@lifescicomms.com

FAQ

When will Entasis Therapeutics report its third quarter 2021 financial results?

Entasis Therapeutics will report its third quarter 2021 financial results on November 4, 2021.

What time is the Entasis Therapeutics conference call on November 4, 2021?

The conference call for Entasis Therapeutics will be held at 8:00 AM Eastern Time on November 4, 2021.

How can I access the Entasis Therapeutics conference call?

You can access the Entasis Therapeutics conference call by dialing 888-394-8218 (U.S.) or 323-701-0225 (international), or through the provided webcast link.

What is the focus of Entasis Therapeutics?

Entasis Therapeutics focuses on the discovery and development of novel antibacterial products for serious infections caused by multidrug-resistant Gram-negative bacteria.

What products are in the pipeline of Entasis Therapeutics?

Entasis Therapeutics has several candidates in its pipeline, including sulbactam-durlobactam for Acinetobacter baumannii infections and zoliflodacin for Neisseria gonorrhoeae infections.